Compare Cytokinetics Inc (CYTK) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Liberty Global Ltd Class C — how do they compare? Cytokinetics Inc trades at $76.45 (market cap $10.63B), while Liberty Global Ltd Class C trades at $10.12 (market cap $3.48B). The key difference: Cytokinetics Inc is far larger — about 3.1× Liberty Global Ltd Class C's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| CYTK | LBTYK | |
|---|---|---|
Market Cap | $10.63B | $3.48B |
Sector | Technology | Technology |
52-Week High | $87.26 | $12.67 |
52-Week Low | $34.31 | $9.59 |
Enterprise Value | $10.74B | $10.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
LBTYK trades at $10.015, up 0.25% on the day, amid a bearish technical signal but strong analyst support. The stock shows mixed earnings, with a Q1 2026 beat but Q4 2025 and Q2 2026 misses, while the company navigates the Ziggo Group spin-off planned for 2027. Financially, it has a low P/S of 0.7 and P/B of 0.37, but negative net income and ROE highlight profitability challenges, offset by solid operating cash flow of $1.21 billion in 2025.
The outlook is cautiously optimistic, with the Ziggo Group listing in 2027 offering a potential catalyst, but persistent losses and competitive pressures pose risks. Analyst consensus is strongly bullish with 69% buy ratings, suggesting underlying value despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
